U.S.-based CRO PPD has added four new practice areas to its consulting services offering: biosimilars, adaptive trial design, regulatory strategy in China, and cardiovascular outcomes studies, according to Pharma Times.
PPD states it has aligned its consulting practice with areas in which clients face significant regulatory and market challenges.
For example, in the field of biosimilar development, PPD stated that its customers can turn to the company for guidance on selecting appropriate endpoints, clinical trial design and developing regulatory strategies.
As for adaptive trial design, PPD says its biostatistics and therapeutic area experts can reduce cycle times and facilitate trial design for efficient, less costly development programs.
PPD already offers services in regulatory, biostatistics and clinical development consulting within therapeutic areas such as oncology, cardiovascular disease, critical care, neurology, psychiatry, infectious diseases and metabolic diseases.